In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation

@article{Chang2018InhospitalDC,
  title={In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation},
  author={San-shuai Chang and Jia-hui Wu and Yi Liu and Ting-Yu Zhang and Xin Du and Jian-zeng Dong and Gregory Y. H. Lip and Changsheng Ma},
  journal={Chronic Diseases and Translational Medicine},
  year={2018},
  volume={4},
  pages={127 - 134},
  url={https://api.semanticscholar.org/CorpusID:49656285}
}
View on PubMed
doi.org
7 Citations
Highly Influential Citations
1
Background Citations
4
Methods Citations
1

Tables from this paper

7 Citations

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China

Aspirin therapy appears to be cost-effective compared with no use of aspirin in primary prevention of CVD in Chinese DM patients.

Cost‐effectiveness of anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation in mainland China

The objective of this study was to evaluate the cost‐effectiveness of NOACs versus warfarin for preventing stroke in patients with NVAF from a Chinese healthcare system perspective.

Cost-Effectiveness of Mobile Health–Based Integrated Care for Atrial Fibrillation: Model Development and Data Analysis

The exploration suggested the potential cost-effective use of mHealth apps in streamlining and integrating care via the Atrial fibrillation Better Care (ABC) pathway for AF in China.

Cost-effectiveness of mobile health-based integrated care for atrial fibrillation: Model development and data analysis (Preprint)

The use of mhealth technology in streamlining and integrating care for AF patients was cost-effective in China, and compliance to mhealth-based care had the greatest impact on the ICER.

Direct Medical Costs of Parkinson’s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City

The direct medical costs of patients with PD in China were high compared to the GDP per capita in Guangzhou City and different between the two evaluated types of insurance.

Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation Analyses.

Evaluation of the “safe multidisciplinary app-assisted remote patient-self-testing (SMART) model” for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial

The design, implementation and usage of the SMART model will provide experience and evidence in developing a novel model for chronic disease management to solve the problem of healthcare service maldistribution, an issue particularly obvious in developing countries during the COVID-19 pandemic.

31 References

Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study

The societal costs attributable to major bleeding events in patients with AF are significant and intracranial haemorrhages are most costly to society with average costs of similar magnitude as the costs of ischemic stroke.

Cost of Acute Stroke Care for Patients with Atrial Fibrillation Compared with Those in Sinus Rhythm

Direct medical costs of acute stroke care for patients with AF may be 50 % greater than for patients without, and economic studies should take this into account to ensure the benefits of anticoagulants are not underestimated.

Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.

Economic Burden of Individual Suffering from Atrial Fibrillation-Related Stroke in China.

Impact of Atrial Fibrillation on Stroke‐Related Healthcare Costs

Stroke‐related care for IS, HS, and TIA is costly, especially among individuals with AF, and reducing the risk of AF‐related stroke is important from both clinical and economic standpoints.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Treatment with rivaroxaban 20 mg once daily was associated with statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily, which indicated increased risk of stroke, bleeding, and mortality in patients with nonvalvular atrial fibrillation.

Hospital Costs Associated With Atrial Fibrillation for Patients With Ischemic Stroke Aged 18–64 Years in the United States

AFib increased the hospital cost of ischemic stroke substantially and the AFib-associated costs for repeat stroke admissions were not significantly higher than for non-AFib patients, except for those aged 55 to 64 years ($3537).

Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation

In conclusion, optimally anticoagulated patients with AF have more favorable functional outcome after stroke and a trend for less severe stroke whereas patients with subtherapeutic antICOagulation have similar stroke severity and outcome with those on no treatment.

Stroke prevention in atrial fibrillation: a systematic review.

An overview of current concepts and recent developments in stroke prevention in Atrial fibrillation, with suggestions for practical management is provided.

Apixaban versus warfarin in patients with atrial fibrillation.

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

Related Papers

Showing 1 through 3 of 0 Related Papers